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Abstract
Background: Non-cell autonomous toxicity is one of the potential mechanisms implicated in the etiopathogenesis
of amyotrophic lateral sclerosis (ALS). However, the exact role of glial cells in ALS pathology is yet to be fully
understood. In a cellular model recapitulating the pathology of sporadic ALS, we have studied the inflammatory
response of astroglia following exposure to the cerebrospinal fluid from ALS patients (ALS-CSF).
Methods: Various inflammatory markers including pro-inflammatory and anti-inflammatory cytokines, COX-2, PGE-2,
trophic factors, glutamate, nitric oxide (NO), and reactive oxygen species (ROS) were analyzed in the rat astroglial
cultures exposed to ALS-CSF and compared with the disease control or normal controls. We used
immunofluorescence, ELISA, and immunoblotting techniques to investigate the protein expression and real-time
PCR to study the messenger RNA (mRNA) expression. Glutamate, NO, and ROS were estimated using appropriate
biochemical assays. Further, the effect of conditioned medium from the astroglial cultures exposed to ALS-CSF on
NSC-34 motor neuronal cell line was detected using the MTT assay. Statistical analysis was carried out using
one-way ANOVA followed by Tukey’s post hoc test, or Student’s t test, as applicable.
Results: Here, we report that the ALS-CSF enhanced the production and release of inflammatory cytokines IL-6 and
TNF-α, as well as COX-2 and PGE-2. Concomitantly, anti-inflammatory cytokine IL-10 and the beneficial trophic
factors, namely VEGF and GDNF, were down-regulated. We also found impaired regulation of glutamate, NO, and
ROS in the astroglial cultures treated with ALS-CSF. The conditioned medium from the ALS-CSF exposed astroglial
cultures induced degeneration in NSC-34 cells.
Conclusions: Our study demonstrates that the astroglial cells contribute to the neuroinflammation-mediated
neurodegeneration in the in vitro model of sporadic ALS.
Keywords: Neuroinflammation, Astrocytes, Cytokines, ROS, COX-2, Trophic factors, ALS
Abbreviations: NC, Normal control; NALS, Non-amyotrophic lateral sclerosis/non-degenerative neurological
diseases; ALS, Amyotrophic lateral sclerosis; IL-6, Interleukin-6; TNF, Tissue necrosis factor; IFN-γ, Interferon gamma;
IL-10, Interleukin-10; NO, Nitric oxide; iNOS, Inducible nitric oxide synthase; ROS, Reactive oxygen species; PGE-
2, Prostaglandin E2; COX-2, Cyclo-oxygenase 2; VEGF, Vascular endothelial growth factor; GDNF, Glial cell line-
derived neurotrophic factor; NC-ACM, Normal control astroglia conditioned medium; ALS-ACM, ALS-CSF exposed
astroglia conditioned medium; NALS-ACM, NALS-CSF exposed astroglia conditioned medium; NSC-
34, Neuroblastoma X spinal cord hybrid cell line; ANOVA, Analysis of variance
* Correspondence: trraju.nimhans.@gmail.com
1Department of Neurophysiology, National Institute of Mental Health and
Neurosciences (NIMHANS), Bangalore 560029, India
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mishra et al. Journal of Neuroinflammation  (2016) 13:212 
DOI 10.1186/s12974-016-0698-0
Background
Etiopathogenesis of amyotrophic lateral sclerosis (ALS),
the devastating and relentlessly progressing neurodegen-
erative disorder leading to muscular weakness, is poorly
understood. Approximately 90 % of the total cases re-
ported have unknown etiology and are categorized as
sporadic ALS. However, the rest 10 % of the cases follow
an autosomal dominant inheritance pattern (familial
ALS/FALS), and only ~20 % of these may be mapped to
the mutations in the SOD-1 gene, which forms the basis
of the animal models of ALS [1]. Apart from the occur-
rence of neuronal death, reports from these mutant
SOD-1 transgenic models, as well as the autopsy studies,
have demonstrated the non-cell autonomous contribu-
tion of the astrocytes in ALS [2–4].
The activated astrocytes may adopt either a neuro-
protective or a neurotoxic phenotype in a stimulus-
dependent manner by a process termed as glial
polarization; the end-results of which depend largely
on the microenvironment experienced by the astro-
cytes [5, 6]. For instance, a neuroprotective role of astro-
cytes has been thoroughly discussed in various
pathological conditions including stroke and spinal cord
injury [7]. On the other hand, astrocytes also respond in a
toxic manner in response to excess ATP or the inflamma-
tory factors like interleukin (IL)-1β and free radicals re-
leased by M1 microglia [8]. Apart from the increased
expression of GFAP and S100β, activated astrocytes may
respond by regulating certain inflammatory, trophic, and/
or toxic factors in the milieu that may act directly on neu-
rons or through other immune cells. These include pro/
anti-inflammatory cytokines, inflammatory markers, and
trophic factors [9, 10].
The plausible role of astrocytes in the initiation/pro-
gression of ALS has been studied employing chimeric
mSOD1/TDP-43 models or human iPSC-derived astro-
cytes from ALS patients [11–13]. Such models have elu-
cidated the possible toxic role of astrocytes in the
pathophysiology of ALS. Lepore et al. [14] investigated
the effect of transplantation of astroglial precursor cells
into the spinal cord of mSOD-1 mice to establish
healthy astroglial pools and demonstrated the mitigation
of the disease symptoms, including a reduction in micro-
gliosis. These findings suggest the important role of as-
trocytes in modulating the inflammatory response.
Glutamate-associated excitotoxicity following the se-
lective loss of astroglial glutamate transporters, leading
to reduced synaptic glutamate uptake, has been reported
in the autopsy samples as well as the animal models of
ALS [3, 15]. However, along with the reduction in glu-
tamate uptake, possibility of pathological release of glu-
tamate by astrocytes as the source of the abnormal
elevation in the glutamate levels in ALS should also be
considered. Some of the early work done indeed suggests
excessive glutamate release in experimental models of
familial ALS, but the source remains unknown [16, 17].
Additionally, glial cells including astrocytes are signifi-
cant contributors to the oxidative stress, another pro-
posed mechanism for the neurodegeneration in ALS
[18]. However, the precise role of astroglia in ALS
pathophysiology remains to be investigated. Further,
most of the current understanding of the role of glia in
ALS is derived from the animal models designed with
genetic mutations/overexpression to recapitulate the dis-
ease symptoms of the familial form, thus precluding
their relevance to the SALS pathogenesis.
To address this, we have established and characterized
a cellular/animal model for SALS, which involves study-
ing the toxic effect of the cerebrospinal fluid from the
sporadic ALS patients (ALS-CSF). Such a model recapit-
ulates the SALS pathology effectively. Using behavioral,
immunocytochemical, molecular, electron microscopy
and electrophysiological approaches, we have earlier
demonstrated the potential of ALS-CSF to induce mor-
phological and functional changes in motor neurons and
glia. This was seen in neurons in the form of
necroptosis-mediated neuronal death, reduced ChAT,
Nav1.6 and Kv1.6 expression, aberrant phosphorylation
of neurofilaments; mitochondrial, Golgi apparatus, ER
and lysosomal defects, and reduced expression of trophic
factors [19–29]. Concomitantly, infusion of ALS-CSF
into the motor cortex of the adult rats caused altered
electrophysiological properties of the motor neurons, as
well as poor motor performance as seen with the rotarod
and grip strength tests [30, 31].
Mass spectrometric analysis of the ALS-CSF demon-
strated a clear up-regulation of glial inflammatory pro-
teins including chitotriosidase, osteopontin, and
chitinases 3 like protein-1 and 2 in the CNS circulation
of the ALS patients, thus emphasizing the role of glia in
SALS pathology [32]. We conducted the present study
to determine the response of astrocytes following expos-
ure to ALS-CSF, thereby elucidating their possible role
in disease initiation and/or progression. To understand
this, we have investigated the expression patterns of
various cytokines, namely IL-6, tissue necrosis factor
(TNF)-α, interferon gamma (IFN-γ), and IL-10, and
trophic factors like vascular endothelial growth factor
(VEGF) and glial cell line-derived neurotrophic factor
(GDNF), as well as inflammation and toxicity mediators
like prostaglandin E2 (PGE-2), cyclo-oxygenase 2 (COX-
2), reactive oxygen species (ROS), nitric oxide (NO), and
glutamate. Additionally, since our model largely takes
into consideration the toxicity mediated by the circulat-
ing fluid of the CNS (ALS-CSF), we also investigated the
effect of the conditioned media containing molecules se-
creted by astroglia, on cultured NSC-34 motor neuron
cell line.




Enriched astrocyte cultures were obtained from Wistar
rats (P0-P2) using a modified protocol of Kerstetter and
Miller [33]. Briefly, the spinal cords were dissected, freed
of meninges, mechanically triturated in Dulbecco’s modi-
fied Eagle’s medium (DMEM), and propagated in DMEM
with 10 % FBS (GIBCO-BRL). The mixed glial cultures
thus obtained were allowed to attain 100 % confluence.
On the 10th day in vitro (DIV), the cultures were spun at
200 rpm for 3–4 h in an incubated orbital shaker. The
medium containing non-astroglial cells was discarded, and
the enriched astroglial monolayer was trypsinized and
replated at a density of 2.5 × 104 cells/ml to avoid contam-
ination with the non-astroglial cells, including microglia
[34]. The astroglial cultures thus obtained were found to
be >99 % pure (Additional file 1: Figure S1). Upon reach-
ing 70–80 % confluence, the cultures were subjected to
different experimental conditions.
NSC-34 cultures
The NSC-34 motor neuronal cell line was procured
(Cedarlane, Canada), maintained, and propagated as per
the published protocol [26]. For experiments, the NSC-34
cells were plated at a density of 2.5 × 104 cells/ml in sterile
24-well plates and allowed to differentiate for 3–4 days in
vitro, or until the cultures attained 70–80 % confluence.
The cultures were then subjected to different experimen-
tal conditions as mentioned below.
CSF collection and exposure
Six drug-naive patients diagnosed to have definite ALS
and the age-matched neurological patients serving as dis-
ease control were selected for CSF collection. The samples
were collected after obtaining informed consent as per the
institutional human ethics committee guidelines. The
diagnosis of ALS was based on the revised El Escorial cri-
teria [35]. The mean age of the SALS patients was
47.17 years (Table 1). Age-matched NALS controls con-
sisted of patients suffering from non-neurodegenerative/
non-inflammatory neurological disorders including ac-
quired peripheral neuropathy, idiopathic intracranial
hypertension, and normal pressure hydrocephalus.
The samples were snap frozen in liquid nitrogen and
stored at −80 °C until further use. For the experiments,
the cultures were exposed to 10 % V/V CSF in DMEM,
and the effects were studied in duplicates for all the six
CSF samples discretely. Thus, depending on the experi-
ments, a minimum of three and a maximum of six sep-
arate cultures were studied in replicates for each
experimental group. The study consisted of three experi-
mental groups, namely:
1. Normal control (NC): cultures propagated in
DMEM
2. NALS (disease control): cultures exposed to CSF
from the age-matched patients suffering from neuro-
logical diseases such as intracranial hypertension
(NALS-CSF, 10 % V/V in DMEM) other than neu-
rodegenerative and neuroinflammatory disorders
3. ALS: cultures exposed to CSF from ALS patients
(ALS-CSF; 10 % V/V in DMEM)
ELISA
ELISA was used to quantify IL-6, IL-10, IFN-γ, and
TNF-α expression in the culture medium. Specific rat
ELISA kits were procured from RayBiotech, Inc
(Georgia, USA), and the standards were prepared ac-
cording to the manufacturer’s instructions. For a tem-
poral analysis, the cultures were exposed to CSF for 12,
24, and 48 h, respectively, and the media from the cul-
tures was used for the estimation.
Glutamate estimation
Approximately 106 cells were harvested from the astroglial
cultures exposed to ALS-CSF or the normal controls for
48 h, and lysates were prepared. Simultaneously, the
medium from the normal controls and each of the subsets
exposed to ALS-CSF for 12, 24, and 48 h was collected
and centrifuged at 14,000 rpm to remove the debris. The
cytosolic and secreted glutamate levels were measured
using the glutamate assay kit (MAK004, Sigma-Aldrich,
USA). The measurement was based on enzymatic conver-
sion, and the absorbance was read at 450 nm using a col-
orimetric ELISA microplate plate reader (Tecan 2500
fluorometer, USA).
Nitric oxide estimation
The lysates from the astroglial cultures exposed to ALS-
CSF for 48 h or the normal controls were prepared as
described above. Simultaneously, the medium from the
normal cultures and those exposed to ALS-CSF was also
collected. The level of nitrates was assayed in the sam-
ples using nitric oxide assay kit (AB65328, Abcam) at
Table 1 Details of the ALS-CSF samples
Gender Male, 4 (66.6 %)
Female, 2 (33.3 %)
Diagnosis Definite, 3 (50 %)
Progressive, 3 (50 %)
Age at presentation (Mean ± SD) 47.17 ± 10.17 (38–65) years
Age at onset (Mean ± SD) 46.37 ± 9.98 (37.5–64) years
Duration of illness (Mean ± SD) 11.3 ± 6.6 (6.0–24) months
Onset pattern Bulbar, 4 (66.6 %)
Limb, 2 (33.3 %)
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540 nm using a colorimetric ELISA microplate reader
(Tecan 2500 fluorometer, USA).
ROS estimation
The ROS levels were measured in astroglial cultures ex-
posed to ALS-CSF using dichlorofluorescin diacetate
(DCFDA), a compound that reacts with the intracellular
ROS to produce fluorescence. Briefly, the cultures were
treated with DCFDA, harvested, and lysed, and the re-
sultant fluorescence release was measured at 536 nm in
an ELISA plate reader. Fluorescence/cell was calculated
and statistically analyzed. For qualitative studies, the
cells were plated onto 13-mm coverslips. After exposure,
the cells were incubated with Locke’s solution and
DCFDA and directly viewed (excitation—480 nm; emis-
sion—530 nm) using confocal microscopy (Leica TCS-
SL, Leica Microsystems, Germany).
MTT assay
Cell viability for NSC-34 cell line was assayed using
MTT assay [36]. Briefly, after 48 h of exposure to the
astroglial-conditioned media, NSC-34 cells were treated
with MTT solution (5 mg/ml, 37 °C). After 2 h, dimethyl
sulfoxide (DMSO) was added to solubilize the resultant
MTT formazan. Absorbance was measured at 570 nm
using an ELISA plate reader, and the percentage of vi-
able cells was statistically analyzed (Tecan 2500
fluorometer, USA).
Quantitative immunofluorescence
Cellular localization, as well as the expression of inflam-
matory molecules and trophic factors, was studied using
quantitative immunofluorescence. Briefly, astroglial cul-
tures were plated at a density of 2.5 × 104 cells/ml onto
the 13-mm circular coverslips pre-coated with poly-l-
lysine (0.1 mg/ml). These were exposed to the aforemen-
tioned experimental conditions for 48 h, after which the
cells were fixed with 4 % paraformaldehyde (PFA) for
15 min at RT. Blocking was carried out with 3 % bovine
serum albumin (BSA) and incubated with primary
antibodies of interest for 24 h, followed by appropriate
secondary antibodies tagged with FITC or CY3 for 2 h
at RT. The specificity was ensured for both primary and
secondary antibodies by adding relevant positive and/or
negative controls to the experiments. For double im-
munofluorescence, the coverslips were re-equilibrated
with 0.1 M PBS (pH 7.4) and blocked with 3 % BSA, fol-
lowing which the second set of primary and secondary
antibodies were added. The list of antibodies, the dilu-
tion factor, incubation time, and the temperature are
provided in Table 2. Finally, the coverslips were
mounted using PVA-DABCO (Sigma-Aldrich, USA) and
viewed under the laser scanning confocal microscope
(Leica TCS-SL, Germany), with excitation wavelengths at
488 and 514 nm for FITC and Cy3, respectively. The
emission frequencies were segregated to avoid non-
specific overlap of labeling. The images thus captured
were quantified for the fluorescence intensities of each
immuno-labeled protein using the inbuilt software of
Leica Microsystems [25, 37]. Briefly, 8-b images were
captured at ×20 magnifications with a constant PMT
voltage, from randomly selected 10 non-overlapping
fields in each coverslip. Other parameters like objective
(20×), optical zoom of 2×, pinhole [airy] (1.000075),
frame average (3), line average (3), resolution (8), frame
(1024 × 1024), and exposure time were also kept con-
stant. We measured the fluorescence intensity graded on
a scale of 0–255, where “0” refers to minimum fluores-
cence and “255” refers to maximum fluorescence on an
8-b image. The region of interest (ROI), i.e., the region
of the each cell where the staining was prominently seen,
was drawn/demarcated using the “poly-line” profile of
the inbuilt software by Leica. Each cell represented a sin-
gle ROI, and a minimum of 20 such cells were quantified
for each image. Thereafter, the image was subjected to
analysis using the inbuilt software, which generated the
numerical values commensurate to the staining. At least
10 such images for each coverslip were randomly ana-
lyzed, thus measuring intensities for least 200 cells per
coverslip (Additional file 2: Figure S2). Each coverslip
Table 2 List of the antibodies used in the study
Primary antibody Secondary antibody
Anti-COX-2 rabbit polyclonal (1:500, Abcam); 24 h, 4 °C Anti-rabbit IgG (Cy3-conjugated; 1:200, Sigma-Aldrich) 2 h, RT
Anti-GDNF mouse monoclonal (1:200, SCBT), 24 h, 4 °C Anti-mouse IgG (Cy3-conjugated; 1:200, Sigma-Aldrich) 2 h, RT
Anti-IFN-γ goat polyclonal (1:200, SCBT) 24 h, 4 °C Anti-goat IgG (Cy3-conjugated; 1:200, Sigma-Aldrich) 2 h, RT
Anti-IL-10 rabbit polyclonal (1:500, Abcam) 24 h, 4 °C Anti-rabbit IgG (Cy3-conjugated; 1:200, Sigma-Aldrich) 2 h, RT
Anti-IL-6 rabbit polyclonal (1:500, Abcam) 24 h, 4 °C Anti-rabbit IgG (FITC-conjugated; 1:200, Chemicon) 2 h, RT
Anti-iNOS rabbit polyclonal (1:800, Abcam) 24 h, 4 °C Anti-rabbit IgG (Cy3-conjugated; 1:200, Chemicon) 2 h, RT
Anti-PGE-2 rabbit polyclonal (1:500, Abcam) 24 h, 4 °C Anti-rabbit IgG (FITC-conjugated; 1:200, Chemicon) 2 h, RT
Anti-TNF-α mouse monoclonal (1:200, Abcam), 24 h, 4 °C Anti-mouse IgG (Cy3-conjugated; 1:200, Sigma-Aldrich) 2 h, RT
Anti-VEGF rabbit polyclonal (1:500 Abcam), 24 h, 4 °C Anti-rabbit IgG (FITC-conjugated; 1:200, Chemicon) 2 h, RT
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corresponded to one replicate of a sample. Five such
samples were analyzed in duplicates for all the three ex-
perimental subsets. Background reduction was applied
for each analysis, and the results were then compared.
Immunoblotting for COX-2, VEGF, and GDNF
Following 48 h of CSF exposure, the astroglial cells were
lysed on ice using cell disruption buffer (AMBION, USA
containing 0.1 % protease inhibitor cocktail (Sigma-
Aldrich)). The lysates thus obtained were centrifuged at
12,000 rpm for 15 min at 4 °C. The suspension was care-
fully collected, and the total protein concentration was de-
termined using Bradford’s reagent. Twenty micrograms of
the protein sample was loaded for each sample. The pro-
teins were separated on 10 % denaturing gel for COX2
and VEGF and 12 % denaturing gel for GDNF, in accord-
ance with the predicted molecular weight. The proteins
were then transferred to PVDF membrane. The mem-
brane was then subjected to blocking with 7 % skimmed
milk overnight at 4 °C. The blots were further incubated
overnight at 4 °C with mouse monoclonal anti-GDNF
(1:1000, SCBT), Rabbit polyclonal anti-VEGF (1:1000,
Abcam), or Rabbit polyclonal anti-COX-2 (1:1000,
Abcam) depending on the experiments, followed by spe-
cific biotinylated anti-mouse for anti-GDNF (1:5000, Vec-
tor Laboratories) and anti-rabbit antibody for anti-VEGF
and anti-COX-2 (1:5000, Vector Laboratories) for 2 h. The
blots were developed using Avidin-Biotin complex and de-
veloping solutions (ABC-AP kit, Vector laboratories). The
bands were visualized, and the intensity was quantified
using the Gel Documentation System (Quantity 1 soft-
ware, Biorad, USA). β-Actin (Sigma-Aldrich) was used as
the loading control, and the band intensity for the protein
of interest was normalized to that of the β-actin protein.
Quantitative RT-PCR
Upon exposure to CSF for 48 h, the astroglial cells were
collected and the total RNA was isolated using RNeasy Plus
Mini Kit (Qiagen, USA) as per the manufacturer’s instruc-
tions. The messenger RNA (mRNA) was quantified using
1 μl of RNA in a NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific Inc). Approximately 10 ng of
RNA was reverse transcribed (RT) using a high-capacity
complementary DNA (cDNA) reverse transcription kit
(Applied Biosystems, USA). Real-time PCR amplification
was carried out in triplicates using specific primers and hy-
drolysis probes for the target genes listed in Table 3, as well
as 18S (endogenous control) in a Rotor Gene-6000 real-
time PCR cycler. The reaction efficiency for the target
genes and 18S was assayed and compared using the stand-
ard curve method, and the assays were standardized until
the PCR efficiency of ~100 ± 10 % was achieved. The cycle
threshold (Ct) values were normalized to the endogenous
control 18S. The relative fold change was calculated using
the comparative CT method (ΔΔCT method) [38].
Statistical analysis
The data for mRNA expression, quantitative immuno-
fluorescence, semi-quantitative western blots, and MTT
assay was statistically assessed for significance by one-
way ANOVA followed by Tukey’s post hoc test. For
ELISA, glutamate, NO, and ROS, the statistical analysis
was carried out using Student’s t test. GraphPad Prism
was the software used to analyze the significance.
Results
ALS-CSF exposure impairs regulation of pro and anti-
inflammatory cytokines
The temporal effect of ALS-CSF on the release of cyto-
kines was determined at three different time points viz.,
12, 24, and 48 h. ALS-CSF exposure resulted in the
enhanced release of pro-inflammatory cytokines IL-6,
TNF-α, and IFN-γ from the astrocytes as compared to the
normal controls (Fig. 1). Increased IL-6 secretion was ob-
served at 48 h (*p < 0.05 NC v/s ALS; Fig.1a), whereas
TNF-α (**p < 0.01 NC v/s ALS, 24 and 48 h; Fig. 1b) and
IFN-γ (*p < 0.05 NC v/s ALS, 24 h and **p < 0.01 NC v/s
ALS, 48 h; Fig. 1c) were up-regulated as early as 24 h with
the levels peaking at 48 h. Concomitantly, a reduction in
the levels of IL-10 was noted beginning at 24 h in cultures
exposed to ALS-CSF as against the normal controls (**p <
0.01 NC v/s ALS, 24 and 48 h; Fig. 1d). A similar effect
was also observed in the cellular levels of the cytokines.
Quantification of the mean immunofluorescence intensity
Table 3 Details of the primers and probes used in the study
Gene Sense primer Anti-sense primer Probe
VEGF GAGCAACGTCACTATCGAGATC GGCTTTGTTCTATCTTTCTTGGTC TGCCGATCAAACCTCACCAAAGCCA
GDNF CGCCGGTAAGAGGCTTCTC GATAATCTTCGGGCATATTGGAGTC CGCCCGCCGAAGACCACTCCCT
IL-6 TCCAGCCAGTTGCCTTCTTG TCCTCTGTGAAGTCTCCTCTCC ACTGATGTTGTTGACAGCCACTGCCTTCC
IL-10 CATGGCCTTGTAGACACCTTTG CATCGATTTCTCCCCTGTGAGA TCATTCTTCACCTGCTCCACTGCCTTGCTT
IFN-γ GCACAAAGCTGTCAATGAACTCA CCAGAATCAGCACCGACTCC CTGTCACCAGAATCTAGCCTAAGGAAGCGG
COX2 CCAACCTCTCCTACTACACCAG GTTCCTTATTTCCTTTCACACCCATG CCTTCCTCCTGTGGCTGATGACTGC
iNOS CATCGACCTGGGCTGGAA CCTCTGGATCTTGACCGTGAG CGATGTGCTGCCTCTGGTCCTGC
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of cultures immunostained for IL-6 and TNF-α proteins
(Fig. 1e–g, graph q and h–j, graph r, respectively), con-
firmed the increased expression of both these proteins in
the ALS subset after 48 h as compared to the NC as well
as the disease (NALS) controls (*p < 0.05 NC and ##p <
0.01 NALS v/s ALS). However, the cellular level of IFN-γ
was stable (Fig. 1k–m, graph s). At 48 h, the cellular IL-10
also remained unaffected, although a minor down-
regulation was noted (Fig. 1n–p, graph t).
Analysis of the mRNA expression of cytokines at 48 h
revealed a sizeable up-regulation of IL-6 (Fig. 1u) and
IFN-γ (Fig. 1v).In cultures exposed to ALS-CSF, we
observed nearly a threefold up-regulation in IL-6 expres-
sion (**p < 0.01 NC and #p < 0.05 NALS v/s ALS) and
approximately fivefold in IFN-γ expression (**p < 0.01
NC and NALS v/s ALS) when compared to the NC sub-
set. Surprisingly, IL-10 mRNA levels were up-regulated
nearly 1.5fold, when compared to NC (*p < 0.05 NC v/s
ALS; Fig. 1w).
COX-2 and PGE-2 expression were up-regulated in
cultures exposed to ALS-CSF
We also studied the expression pattern of both COX-2
and PGE-2 in astrocyte cultures following exposure to
Fig. 1 Pro-inflammatory cytokines are up-regulated in response to ALS-CSF: exposure of astrocytes to ALS-CSF caused a progressive up-regulation in
the secretion of IL-6 (a; *p < 0.05 NC v/s ALS, 48 h; n = 3 in duplicates), TNF-α (b; **p < 0.01 NC v/s ALS, 24 and 48 h; n = 3 in duplicates), and IFN-γ
(c; *p < 0.05, 24 h and **p < 0.01 NC v/s ALS, 48 h; n = 3 in duplicates), while a down-regulation in the IL-10 levels was observed (d; **p < 0.01 NC v/s
ALS, 24 and 48 h; n = 3 in duplicates). The protein levels were determined by ELISA. e–p The confocal images representing the cellular expression of
the cytokines in the normal controls as compared to the cultures exposed to NALS/ALS-CSF. Analysis of the mean fluorescence intensity (MFI) revealed
a qualitative as well as a quantitative increase in the expression of IL-6 (green, e–g; graph q; *p < 0.05 NC v/s NALS and ALS; n = 5 in duplicates) and
TNF-α (red, h–j; graph r, #p < 0.05 NC v/s ALS and **p < 0.01 NALS v/s ALS; n = 5 in duplicates). However, the cellular levels of IFN-γ (red, k–m; graph s;
n = 5 in duplicates) and IL-10 (green, n–p; graph t; n = 5 in duplicates) did not show any significant changes in the cultures exposed to ALS-CSF. Graphs
u–w represent the mRNA expression levels of IL-6, IFN-γ, and IL-10, respectively, in response to ALS-CSF. Note the up-regulation in IL-6 (**p < 0.01 NC
and #p < 0.05 NALS v/s ALS; n = 3 in triplicates; u), IFN-γ (**p < 0.01 NC and NALS v/s ALS; n = 3 in triplicates; v), and IL-10 mRNA expression (*p < 0.05
NC v/s ALS; n = 3 in triplicates; w) when exposed to ALS-CSF. Analysis of significance was carried out using Student’s t test for ELISA and one-way
ANOVA followed by Tukey’s post hoc test for determining the MFI as well as the mRNA expression. Scale bars for confocal images are indicated
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ALS-CSF. We observed a significant up-regulation in
the mRNA expression of COX-2 (**p < 0.01 NC and
NALS vs. ALS; Fig. 2a). The immunofluorescence pat-
tern revealed that COX-2 and PGE-2 exhibited a punc-
tate cytoplasmic staining in astrocytes (Fig. 2d–l).
Quantification of the mean fluorescence intensity also
showed a significant increase in the levels of COX-2 pro-
tein expression as compared to NC and NALS subsets
(**p < 0.01 NC and NALS v/s ALS; Fig. 2m). The results
were further validated by the increased expression of
COX-2 in ALS-CSF compared to the normal and disease
control, as determined by the western blot analysis (*p <
0.05 NC and NALS v/s ALS; Fig. 2b, c). In a similar
manner, ALS-CSF caused up-regulation of PGE-2 levels,
while NALS-CSF did not, and was comparable to the
normal controls (***p < 0.001 NC and NALS v/s ALS;
Fig. 2n).
ALS-CSF enhances production and release of astroglial
glutamate
We compared the levels of astroglial glutamate upon ex-
posure to ALS-CSF (Fig. 3a–c). The secreted glutamate
levels were significantly elevated in ALS subsets as com-
pared to the normal controls only at 48 h (*p < 0.05 NC v/
s ALS), but not at 12 or 24 h (Fig. 3a). The astroglial ly-
sates too showed a significant increase in the glutamate
levels when compared to the normal control (**p < 0.01
NC v/s ALS; Fig. 3b). Thus, a concomitant increase in the
Fig. 2 ALS-CSF induces inflammatory response by astrocytes: COX-2 mRNA expression was seen up-regulated in response to ALS-CSF (**p< 0.01 NC and
NALS vs. ALS, n= 5 in triplicates; graph a), suggesting the induction of neuroinflammatory pathways. Note the significant up-regulation in the COX-2
protein expression in the ALS group, as observed by western blot analysis (b,*p< 0.05 NC and NALS vs. ALS; n= 3; graph c). Representative confocal images
of the cultures immunostained for COX-2 (FITC, green; d–f; **p< 0.01 NC and NALS vs. ALS; n= 5 in duplicates; graph m) and its downstream inflammatory
molecule PGE-2 (Cy3, red, g–i; ***p< 0.001 n= 5 in duplicates; graph n) further demonstrate the inflammatory potential of the astroglial cells in response to
ALS-CSF. Analysis of the significance was carried out using one-way ANOVA followed by Tukey’s post hoc test. Scale bars are indicated
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Fig. 3 (See legend on next page.)
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cytosolic, as well as secreted glutamate levels, was seen in
the ALS group by 48 h (Fig. 3c and Table 4). This observa-
tion strongly suggests excessive glutamate production, in
addition to secretion occurring in response to ALS-CSF.
ALS-CSF induced enhanced release of astroglial nitric
oxide and ROS
We then analyzed the astroglial ROS and NO levels,
considering the inflammatory and toxic phenotype
adopted by the astrocytes in response to ALS-CSF. Ana-
lysis of lysates revealed a significant increase in the
amount of cytosolic NO in astroglial cultures exposed to
ALS-CSF at 48 h, when compared to the normal con-
trols, but not at 12 or 24 h (**p < 0.01 NC v/s ALS;
Fig. 3d, Table 5). The secreted NO levels were also
higher in the ALS-CSF exposed cultures lysates at 48 h
(**p < 0.01 NC v/s ALS; Fig. 3e and Table 5). To deter-
mine the source of the pathological amounts of NO, the
expression of iNOS was studied. Analysis of the mRNA
expression (**p < 0.01 NC v/s ALS; Fig. 3l) and quantita-
tive analysis of the mean immunofluorescence intensity
demonstrated an up-regulation of the iNOS protein in
ALS subset compared to the normal controls (***p <
0.001 NC v/s ALS; Fig.3k).
Qualitative assessment of the cytosolic ROS by confocal
microscopy also revealed enhanced ROS levels in cultures
exposed to ALS-CSF for 48 h when compared to the nor-
mal control (Fig. 3i, j). Further, a quantitative fluorometric
assessment of the ROS levels in NC and ALS cellular ly-
sates showed a significantly higher ROS levels in the ALS
group (***p < 0.001 NC v/s ALS; graph m).
Decline in trophic factor expression accompanied
neuroinflammation
Further, to investigate the effect of ALS-CSF on the
trophic factors secreted by astrocytes, we analyzed the
mRNA and protein levels of GDNF and VEGF. ALS-
CSF exposure resulted in near threefold down-regulation
in the mRNA expression levels of GDNF in the astroglial
cultures exposed to ALS-CSF for 48 h, when compared
to the normal and the disease control (**p < 0.01 NC and
#p < 0.05 NALS v/s ALS; Fig. 4a). In line with the mRNA
expression, the mean immunofluorescence intensity for
GDNF protein was also down-regulated in the ALS
group (**p < 0.01 NC and NALS v/s ALS; Fig. 4c–e,
graph i). The semi-quantitative western blot analysis fur-
ther validated the results (*p < 0.05 NC and ##p < 0.01
NALS v/s ALS; Fig. 4c–e, graph i).
We also observed an approximately fourfold down-
regulation of VEGF mRNA level as compared to NC
and NALS subsets (***p < 0.001 NC and ##p < 0.01 NALS
v/s ALS; Fig. 4b). Further, the quantitative analysis of the
mean fluorescence intensity also confirmed a down-
regulation in the astroglial VEGF protein expression as
compared to the NC and NALS subsets (**p < 0.01 NC
and NALS v/s ALS, Fig. 4f–h, graph j). Similarly, a re-
duction in VEGF protein expression in the ALS subsets
was also observed with western blot analysis (*p < 0.05
NC and NALS v/s. ALS; graph m).
The secreted astroglial factors contributed to motor
neuronal toxicity
The functional changes thus observed indicated an in-
flamed and toxic phenotype of astroglia, bereft of its
(See figure on previous page.)
Fig. 3 Astrocytes secrete increased levels of glutamate, ROS, and NO in response to ALS-CSF and impart neurotoxicity to NSC-34 cells. a–c Graphs
representing the up-regulation in the glutamate synthesis and secretion by astrocytes. Glutamate secretion was up-regulated in the astroglial supernatants
48 h after the exposure to ALS-CSF as compared to NC (*p< 0.05 NC v/s ALS; n= 5 in duplicates; graph a). Also, note the up-regulated expression in the
cellular glutamate (**p< 0.01 NC v/s ALS; n= 5 in duplicates; graph b). Taken together, the total increase in the astroglial glutamate levels is evident as
plotted in graph c (**p< 0.01 NC v/s ALS; n= 5 in duplicates). Similarly, the secreted (**p< 0.01 NC v/s ALS 48 h, n= 5 in duplicates, graph d), cellular
(**p< 0.01 NC v/s ALS, n= 5 in duplicates, graph e), and total expression levels (***p< 0.001 NC v/s ALS; n= 5 in duplicates; graph f) of NO showed up-
regulation in response to a 48-h exposure to ALS-CSF as compared to NC. The confocal images g, h (CY3, red) represent the expression patterns of iNOS in
the NC and ALS subsets, respectively. Note the enhanced expression of iNOS in ALS group, as determined by the MFI (***p< 0.001 NC v/s ALS; n= 5 in
duplicates, graph k). Also note the increased mRNA expression of iNOS in response to the ALS-CSF as compared to the normal controls (**p< 0.01 NC v/s
ALS; n= 3 in triplicates; graph l). Representative confocal images for the cellular levels of (DCFDA, green, i, j) as well as quantitative fluorometric analysis
(graph m) denote an increased ROS expression in ALS subsets as compared to the NC (***p< 0.001 NC v/s ALS; n= 6 in triplicates). Analysis of significance
was carried out using Student’s t test. Scale bars are indicated
Table 4 Summary of the astroglial cytosolic and secreted
glutamate levels (ng/ml) at 48 h after the CSF exposure
NC ALS
Cytosolic 0.42 ± 0.04 3.13 ± 1.08**
Secreted 16.18 ± 0.53 24.25 ± 3.279*
Overall 16.62 ± 0.57 28.82 ± 3.04**
Values are expressed as Mean ± SEM
*p < 0.05; **p < 0.01
Table 5 Summary of the cytosolic and secreted levels of NO
(ng/ml), 48 h after the exposure to ALS-CSF
NC ALS
Cytosolic 3.59 ± 0.41 5.3 ± 0.44 **
Secreted 4.96 ± 0.17 6.11 ± 0.18**
Overall 8.22 ± 0.27 12.50 ± 1.0***
Values are expressed as Mean ± SEM
**p < 0.01; ***p < 0.001
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Fig. 4 Down-regulated trophic factor expression in response to ALS-CSF. Graphs a, b denote the down-regulation in the mRNA levels of GDNF (**p< 0.01
NC and #p< 0.05 NALS v/s ALS; n= 5 in triplicates) and VEGF (***p< 0.001 NC and ##p< 0.01 NALS v/s ALS; n= 5 in triplicates), respectively, upon exposure
to ALS-CSF as compared to normal and disease controls. The down-regulation in mRNA expression was followed by a reduction in the protein expression
for both the proteins, as observed by western blotting as well as immunofluorescence. The representative confocal images and quantitative analysis of MFI
indicate a down-regulated expression of GDNF (c–e, graph i; **p< 0.01 NC and NALS v/s. ALS; n= 5 in duplicates) and VEGF (f–h, graph j, **p< 0.01 NC
and NALS vs. ALS; n= 5 in duplicates), respectively, in the cultures exposed to ALS-CSF as compared to the normal controls. Scale bars are indicated. The
dysregulation was further validated by the semi-quantitative western blot (k) analysis suggesting a decreased expression of both, GDNF (graph l; *p< 0.05
NC v/s, and ##p< 0.01 NALS v/s. ALS; n= 3 in duplicates), as well as VEGF (graphm; *p< 0.05 NC and NALS v/s. ALS; n= 3 in duplicates) in response to
ALS-CSF. Analysis of significance was carried out using one-way ANOVA followed by Tukey’s post hoc test
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trophic support to neurons. Therefore, to substantiate
the astroglial-mediated pathology, we investigated the ef-
fect of astroglial secretions on the NSC-34 motor neur-
onal cell line. This was achieved by growing the NSC-34
cells in the conditioned media from the astroglial cul-
tures exposed to either ALS-CSF (ALS-ACM) or NALS-
CSF (NALS-ACM) as disease control. For the normal
control, NSC-34 cells were exposed to conditioned
media from the astroglial cultures grown in normal
medium (NC-ACM).
Upon exposure, ALS-ACM induced morphological
changes suggestive of degeneration in NSC-34 cells,
while the cells appeared healthy in NC-ACM and
NALS-ACM (Fig. 5a–c). ALS-ACM induced vacuol-
ation, clumping, and beading of neurites in NSC-34
cells. The number of undifferentiated cells increased in
response to ALS-CSF exposure.
Further, there was a 25 % reduction in the cell viability
in cultures exposed to ALS-ACM when compared to
NALS-ACM and NC-ACM (***p < 0.001 NC-ACM and
NALS-ACM v/s ALS-ACM; Fig. 5d). These results are
comparable to our previous observations on the neuro-
degenerative potential of ALS-CSF [26].
Discussion
Our present study outlines the inflammatory and toxic
functional alterations in astrocytes in SALS and provides a
composite picture of their role in exacerbating neurodegen-
eration. It also provides proof of the concept of an intricate
pathological process with convergent pathways, involving
oxidative stress, excess glutamate and nitric oxide, inflam-
mation, and reduced trophic support thus initiating a cas-
cade of events leading to motor neuronal insult.
Our previous studies showed that the activated astro-
cytes undergo hypertrophy and transform from a flat or
protoplasmic morphology to a process bearing, i.e., fibrous
shape, along with the down-regulation of glial glutamate
transporter (GLT1) in response to ALS-CSF [39]. Here,
we report that the astrocytes also undergo functional
changes and contribute to inflammation-mediated tox-
icity. Further, qualitative observations revealed that the in-
crease in the pro-inflammatory cytokines was more
evident in the process bearing astrocytes.
Pro-inflammatory cytokines have gained notoriety for
their role in triggering and propagating inflammation-
mediated neurotoxicity [40]. The up-regulation of IL-6,
IFN-γ, and TNF-α in both mRNA as well as protein levels
in response to ALS-CSF suggests that the inflammatory
factors like Chit-1, osteopontin, and other chitinases up-
regulated in ALS-CSF could enhance the synthesis and
secretion of these cytokines, thus promoting a vicious in-
flammatory cycle. Of particular relevance is the temporal
sequence of cytokine release in the disease pathology. The
peak expression of TNF-α and IFN-γ at 24 h and that of
IL-6 at 48 h clearly establishes that IL-6 up-regulation is a
downstream event. Mir and colleagues [41] noted that
apart from inducing inflammatory signaling, TNF-α, and
IFN-γ in the presence of inflamed glial cells are jointly
capable of inducing oxidative stress and motor neuronal
death. The role of IL-6 in acute phase reaction, as well as
chronic inflammation, is well studied [42, 43]. Our data
suggests a role for IL-6 in mediating sustained chronic in-
flammation in pathological conditions. Additionally, its
contribution in mediating a switch from innate to adaptive
immunity is well documented [44].
IL-10 is a beneficial anti-inflammatory cytokine. Vaso-
active intestinal peptide (VIP) exerts its immune modula-
tory actions by regulating IL-10 as well as neurotrophic
factors in an mSOD1 model of ALS [45]. Similarly, Ayers et
al. [46] showed that IL-10 expression in the spinal axis pro-
longed the survival of SOD1-G93A mice. Thus, reduced ex-
pression of IL-10 protein component despite the up-
regulation of its mRNA levels hints towards the inability of
astrocytes to counter the ALS-CSF induced neurotoxic
Fig. 5 ALS-CSF conditioned astroglial medium imparts neurotoxicity to NSC-34 cells (a–c). The phase contrast images of NSC-34 cells depicting
the effect of the conditioned media from astroglial cultures exposed to NALS/ALS-CSF (NALS/ALS-ACM) or NC (NC-ACM). Note the extensive
vacuolation (c, arrowhead) and dying cells (c, arrow) in ALS-ACM subsets. The corresponding graph (graph d) shows a significant reduction in the
percent cell viability as measured by altered pattern of MTT reduction, in the NSC-34 cells exposed to ALS-ACM as compared to the NC-ACM or
NALS-ACM groups (***p < 0.001 NC v/s ALS; n = 5 in triplicates). Analysis of significance was carried out using one-way ANOVA followed by
Tukey’s post hoc test. Scale bar is indicated
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insult and may be denoted as a “quasi-compensatory” re-
sponse, which requires further investigation. Although we
did observe a trend of temporally mediated up-regulation
in the IL-10 expression under normal conditions, it was re-
latable to the increase in basal IL-10 levels of the normal
controls as reported earlier and might be a physiological,
rather than experimental, phenomenon [47].
Further, pro-inflammatory cytokines can regulate the
glutamatergic transmission by directly inhibiting astro-
glial glutamate transporters, by inducing overexpression
of glutamate receptors on synapses or by reducing glu-
tamate uptake via NO-mediated mechanism [48, 49]. Al-
though excitotoxicity due to excess synaptic glutamate
in ALS has been widely attributed to a reduction in
astroglial glutamate transporters [3, 15], the possibility
of enhanced glutamate secretion needed to be explored.
Here, we provide objective evidence that in addition to
the reduced uptake of glutamate, astroglial cells release
more glutamate, which may result in its accumulation in
the microenvironment of motor neurons. Reports of the
microvesicular release of glutamate from astrocytes in
response to insults corroborate our interpretation [50].
The inflammatory role of COX-2 and PGE-2 has been
demonstrated in ALS, while their role in conferring neuro-
protection or toxicity in inflammation is debated [51]. Con-
sidering the neurotoxic potential of astroglia in our study,
elevated levels of COX-2 and PGE-2 could further aggra-
vate the pathology. It is noteworthy that PGE-2, NO, and
ROS are also potential effectors of glutamate release
[52–54]. The excess glutamate released thus can lead to
neurotoxicity through the induction of necrosis, in associ-
ation with ROS, NO, and abnormal Ca2+ influx, as reported
in the case of acute viral encephalomyelitis and PD [55].
Up-regulation of astroglial ROS, NO, and iNOS levels in
response to ALS-CSF was another major finding. Elevated
levels of ROS accentuate the disease pathology by causing
oxidative stress, as well as reducing the glutathione (GSH)
levels [56, 57]. Similarly, apart from the free radical-
mediated damage, NO is capable of inflicting neurodegen-
eration through apoptosis, which concurs with our previous
report of the occurrence of both necrosis and apoptosis,
i.e., “necroptosis” induced neuronal death in the disease
pathogenesis [21, 25, 26]. NO may also regulate post-
translational modifications to affect the synaptic transmis-
sion and vesicular release [58, 59]. Such effects are generally
brought about by excessive production of NO, mediated by
either overactivation of n-NOS or pathological induction of
iNOS [59]. Our results demonstrating the increased NO
production and up-regulated expression of iNOS protein
suggest the polarization of astrocytes to respond in a neuro-
toxic manner on exposure to ALS-CSF.
In the present study, we also report the capability of
the conditioned medium, here representing the secreted
factors, to exert neurotoxicity comparable to that of our
ALS-CSF model of pathology, thus validating the role of
astrocytes in the disease progression. Recently, Rojas
and colleagues demonstrated that the astroglial-
conditioned media from mSOD1 model brought about
mitochondrial dysfunction, ROS elevation, and Ca2+ in-
flux in normal glial cells, as well as neurons [60]. The
ability of the conditioned media from these cultures to
exert toxicity to neurons, as well as propagating path-
ology to glial cells, provides further proof to our own
model of the propagation of pathology through the cir-
culating fluid (ALS-CSF).
Concomitant to the inflammatory and toxic changes
observed in the astrocytes, we also observed the down-
regulation of the neurotrophic factors, VEGF and GDNF.
They may protector reverse the motor neuron degener-
ation since trophic factor supplementation has been
reported to be beneficial [25, 61]. Matsushita and col-
leagues [62] reported a significant down-regulation of
GDNF in response to endotoxin LPS, suggesting its rele-
vance in inflammation-mediated pathology. The down-
regulation of these trophic factors in astrocytes, along
with the previous reports of lower trophic levels in
motor neurons in ALS and also during inflammation
thus hint towards a possible cessation of trophic support
in the inflammation-mediated neurodegeneration.
Conclusions
In conclusion, the up-regulation of pro-inflammatory cyto-
kines and down-regulation of anti-inflammatory cytokine
suggest a clear ALS-CSF-induced astroglial cytokine imbal-
ance. The multifarious nature of astroglial involvement in
ALS pathogenesis is implied by the increase in auxiliary
pro-inflammatory factors like PGE-2, COX-2, NO, and glu-
tamate. The depletion of endogenous astrocytic VEGF and
GDNF provide the additional impounding effect. Such a
plethora of responses encompassing the inflammatory
process suggests a temporal hierarchy of the pathways and
molecules involved. Based on our results, we would like to
advocate the need for combinatorial therapies to combat
the multidimensional glial pathology and its compounding
effect on the degeneration of motor neurons.
Additional files
Additional file 1: Figure S1. Representative phase contrast (a, c–e) and
confocal images of the enriched astroglial cultures (b, f–h). The reactive
astrocytes display a process bearing morphology (e, h) as compared to the
flat morphology adopted by the non-reactive astrocytes (c, f). The
intermediate stages show a semi-reactive morphology with a transformation
from flat to process bearing one (d, g). The cultures were found to be free
of microglia as seen by the presence of GFAP immunoreactivity (red, j) and
absence of Iba1 (green, i). In a similar manner, the cultures were found to
be ChAT negative (green, l). The cultures were >99 % pure. Scale bars are
indicated. (TIF 14438 kb)
Additional file 2: Figure S2. Quantification using the inbuilt Leica
software (a). The white arrowhead represents the fluorescent area
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selected for the intensity measurement using poly-line profile for each
cell, referred to as the region of interest (ROI). Twenty cells per image
were considered for each of the 10 images taken per cover slip. b The
report generated by the software. The mean intensity was taken for each
ROI and further analyzed. (TIF 7393 KB)
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